{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:22:35Z","timestamp":1792110155429,"version":"4.4.0"},"reference-count":79,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. They are ligand-activated transcription factors and exist in three different isoforms, PPAR\u03b1 (NR1C1), PPAR\u03b2\/\u03b4 (NR1C2), and PPAR\u03b3 (NR1C3). PPARs regulate a variety of functions, including glucose and lipid homeostasis, inflammation, and development. They exhibit tissue and cell type-specific expression patterns and functions. Besides the established notion of the therapeutic potential of PPAR agonists for the treatment of glucose and lipid disorders, more recent data propose specific PPAR ligands as potential therapies for cardiovascular diseases. In this review, we focus on the knowledge of PPAR function in myocardial infarction, a severe pathological condition for which therapeutic use of PPAR modulation has been suggested.<\/jats:p>","DOI":"10.3390\/ijms21249436","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T23:39:36Z","timestamp":1607902776000},"page":"9436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["PPARs and Myocardial Infarction"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-7760","authenticated-orcid":false,"given":"Kay-Dietrich","family":"Wagner","sequence":"first","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CNRS, INSERM, iBV, 06107 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-0707","authenticated-orcid":false,"given":"Nicole","family":"Wagner","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, CNRS, INSERM, iBV, 06107 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pharmthera.2009.12.001","article-title":"Peroxisome proliferator-activated receptor beta\/delta (PPAR\u03b2\/\u03b4) acts as regulator of metabolism linked to multiple cellular functions","volume":"125","author":"Wagner","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003495-198800363-00009","article-title":"Helsinki Heart Study. New perspectives in the prevention of coronary heart disease","volume":"36","author":"Huttunen","year":"1988","journal-title":"Drugs"},{"key":"ref_3","first-page":"645","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nat. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jacc.2007.09.048","article-title":"Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: An extended follow-up of the BIP trial","volume":"51","author":"Goldenberg","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"New Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1096\/fj.01-0793com","article-title":"Ligands of the peroxisome proliferator-activated receptors (PPAR-\u03b3 and PPAR-\u03b1) reduce myocardial infarct size","volume":"16","author":"Wayman","year":"2002","journal-title":"FASEB J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1161\/01.CIR.0000093187.42015.6C","article-title":"Activation of Peroxisome Proliferator\u2013Activated Receptor-\u03b1 Protects the Heart From Ischemia\/Reperfusion Injury","volume":"108","author":"Yue","year":"2003","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"H87","DOI":"10.1152\/ajpheart.00285.2005","article-title":"Chronic activation of PPAR\u03b1 is detrimental to cardiac recovery after ischemia","volume":"290","author":"Sambandam","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"H1899","DOI":"10.1152\/ajpheart.01014.2005","article-title":"Effects of chronic activation of peroxisome proliferator-activated receptor-\u03b1 or high-fat feeding in a rat infarct model of heart failure","volume":"290","author":"Morgan","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"H1798","DOI":"10.1152\/ajpheart.00631.2005","article-title":"The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs","volume":"290","author":"Xu","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"H719","DOI":"10.1152\/ajpheart.00394.2008","article-title":"PPAR-\u03b1 activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: Involvement of the PI3-Kinase\/Akt and NO pathway","volume":"296","author":"Bulhak","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lfs.2014.03.019","article-title":"Cardiomyocyte specific peroxisome proliferator-activated receptor-\u03b1 overexpression leads to irreversible damage in ischemic murine heart","volume":"102","author":"Duerr","year":"2014","journal-title":"Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ibarra-Lara, L., S\u00e1nchez-Aguilar, M., Soria-Castro, E., Vargas-Barr\u00f3n, J., Rold\u00e1n, F.J., Pav\u00f3n, N., Torres-Narv\u00e1ez, J.C., Cervantes-P\u00e9rez, L.G., Pastel\u00edn-Hern\u00e1ndez, G., and S\u00e1nchez-Mendoza, A. (2019). Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model. Molecules, 24.","DOI":"10.3390\/molecules24020270"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109487","DOI":"10.1016\/j.biopha.2019.109487","article-title":"Ginsenoside Rb3 regulates energy metabolism and apoptosis in cardiomyocytes via activating PPAR\u03b1 pathway","volume":"120","author":"Chen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FJC.0b013e31804b4163","article-title":"PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure","volume":"50","author":"Jucker","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7631085","DOI":"10.1155\/2016\/7631085","article-title":"Inducible Conditional Vascular-Specific Overexpression of Peroxisome Proliferator-Activated Receptor Beta\/Delta Leads to Rapid Cardiac Hypertrophy","volume":"2016","author":"Wagner","year":"2016","journal-title":"PPAR Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Park, J.R., Ahn, J.H., Jung, M.H., Koh, J.-S., Park, Y., Hwang, S.-J., Jeong, Y.-H., Kwak, C.H., Lee, Y.S., and Seo, H.G. (2016). Effects of Peroxisome Proliferator-Activated Receptor-\u03b4 Agonist on Cardiac Healing after Myocardial Infarction. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148510"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/cr.2017.84","article-title":"Live cell screening platform identifies PPAR\u03b4 as a regulator of cardiomyocyte proliferation and cardiac repair","volume":"27","author":"Magadum","year":"2017","journal-title":"Cell Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1161\/hc4601.099403","article-title":"In Vivo Myocardial Protection From Ischemia\/Reperfusion Injury by the Peroxisome Proliferator\u2013Activated Receptor-\u03b3 Agonist Rosiglitazone","volume":"104","author":"Yue","year":"2001","journal-title":"Circ."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/01.LAB.0000106724.29121.DA","article-title":"Pioglitazone, a Peroxisome Proliferator-Activated Receptor-Agonist, Attenuates Myocardial Ischemia\/Reperfusion Injury in a Rat Model","volume":"83","author":"Ito","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"H687","DOI":"10.1152\/ajpheart.00926.2005","article-title":"Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42\/44 MAPK","volume":"291","author":"Molavi","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2006.03.060","article-title":"Effect of peroxisome proliferator-activated receptor \u03b3 ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction","volume":"113","author":"Geng","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000100870","article-title":"Effect of Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Agonist, on Ischemia-Reperfusion Injury in Rats","volume":"79","author":"Cao","year":"2007","journal-title":"Pharmacology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/SHK.0b013e31815dbdc3","article-title":"Rosiglitazone is cardioprotective in a murine model of myocardial I\/R","volume":"30","author":"Mersmann","year":"2008","journal-title":"Shock"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvn308","article-title":"Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation\u2014A novel mechanism for the cardioprotective effects of PPAR agonists","volume":"81","author":"Liu","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"H1558","DOI":"10.1152\/ajpheart.00712.2008","article-title":"Antidiabetic drug pioglitazone protects the heart via activation of PPAR-\u03b3 receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction","volume":"296","author":"Yasuda","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1681.2009.05232.x","article-title":"Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase\/Akt-dependent pathway","volume":"37","author":"Zhang","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/CIRCRESAHA.109.211797","article-title":"Adiponectin: An indispensable molecule in rosiglitazone cardioprotection following myocardial infarction","volume":"106","author":"Tao","year":"2009","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/labinvest.2011.45","article-title":"Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma","volume":"91","author":"Maejima","year":"2011","journal-title":"Lab. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/stem.574","article-title":"Pretreatment of Human Mesenchymal Stem Cells with Pioglitazone Improved Efficiency of Cardiomyogenic Transdifferentiation and Cardiac Function","volume":"29","author":"Shinmura","year":"2011","journal-title":"Stem Cells"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s12015-015-9615-7","article-title":"Peroxisome Proliferator-Activated Receptor Gamma Promotes Mesenchymal Stem Cells to Express Connexin43 via the Inhibition of TGF-\u03b21\/Smads Signaling in a Rat Model of Myocardial Infarction","volume":"11","author":"Hou","year":"2015","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16406","DOI":"10.1038\/srep16406","article-title":"Lysophosphatidic acid enhances survival of human CD34+ cells in ischemic conditions","volume":"5","author":"Kostic","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_33","first-page":"5765","article-title":"Dual PPAR\u03b1\/\u03b3 ligand TZD18 improves myocardial metabolic remodeling after myocardial infarction in rats","volume":"21","author":"Chen","year":"2017","journal-title":"Eur. Rev. Med Pharmacol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.atherosclerosis.2018.05.005","article-title":"Myeloid peroxisome proliferator-activated receptor gamma deficiency aggravates myocardial infarction in mice","volume":"274","author":"Shen","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/cvr\/cvy200","article-title":"Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte\/macrophage polarization in preclinical animal models","volume":"115","author":"Tokutome","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-019-0829-x","article-title":"Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype","volume":"18","author":"Mori","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2015.03.021","article-title":"Effects of the dual peroxisome proliferator\u2013Activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes","volume":"170","author":"Erdmann","year":"2015","journal-title":"Am. Hear. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1042\/CS20070391","article-title":"Association between PPAR\u03b1 gene polymorphisms and myocardial infarction","volume":"115","author":"Reinhard","year":"2008","journal-title":"Clin. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.amjcard.2008.02.052","article-title":"Cholesterol Ester Transfer Protein, Interleukin-8, Peroxisome Proliferator Activator Receptor Alpha, and Toll-Like Receptor 4 Genetic Variations and Risk of Incident Nonfatal Myocardial Infarction and Ischemic Stroke","volume":"101","author":"Enquobahrie","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.RES.0000060700.55247.7C","article-title":"Peroxisome Proliferator-Activated Receptor (PPAR) \u03b1 and PPAR\u03b2\/\u03b4, but not PPAR\u03b3, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism","volume":"92","author":"Gilde","year":"2003","journal-title":"Circ. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm1116","article-title":"Cardiomyocyte-restricted peroxisome proliferator-activated receptor-\u03b4 deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy","volume":"10","author":"Cheng","year":"2004","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/jmri.20766","article-title":"Open-chest31P magnetic resonance spectroscopy of mouse heart at 4.7 Tesla","volume":"24","author":"Lee","year":"2006","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_45","first-page":"2045894018812053","article-title":"PPAR\u03b2\/\u03b4 a potential target in pulmonary hypertension blighted by cancer risk","volume":"9","author":"Mitchell","year":"2018","journal-title":"Pulm. Circ."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wagner, K.D., Du, S., Martin, L., Leccia, N., Michiels, J.-F., and Wagner, N. (2019). Vascular PPAR\u03b2\/\u03b4 Promotes Tumor Angiogenesis and Progression. Cells, 8.","DOI":"10.3390\/cells8121623"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wagner, N., and Wagner, K.D. (2020). PPAR Beta\/Delta and the Hallmarks of Cancer. Cells, 9.","DOI":"10.3390\/cells9051133"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/hr.2013.157","article-title":"Telmisartan activates endogenous peroxisome proliferator-activated receptor-\u03b4 and may have anti-fibrotic effects in human mesangial cells","volume":"37","author":"Mikami","year":"2013","journal-title":"Hypertens. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/hr.2012.17","article-title":"Structural basis for telmisartan-mediated partial activation of PPAR gamma","volume":"35","author":"Amano","year":"2012","journal-title":"Hypertens. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR\u03b3\u2013Modulating Activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.111.086660","article-title":"Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: Analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial (ONTARGET)","volume":"126","author":"Kappert","year":"2012","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejheart.2007.11.005","article-title":"Up-regulation of PPAR\u03b3 in myocardial infarction","volume":"10","author":"Fliegner","year":"2008","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1042\/CS20100466","article-title":"Remote preconditioning provides potent cardioprotection via PI3K\/Akt activation and is associated with nuclear accumulation of \u03b2-catenin","volume":"120","author":"Li","year":"2011","journal-title":"Clin. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cvr\/cvp106","article-title":"Peroxisome proliferator-activated receptor \u03b2 stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin","volume":"83","author":"Wagner","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wagner, N., and Wagner, K.-D. (2020). PPARs and Angiogenesis\u2014Implications in Pathology. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165723"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study","volume":"26","author":"Delea","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes","volume":"356","author":"Nissen","year":"2007","journal-title":"New Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","article-title":"Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated with Rosiglitazone or Pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","article-title":"Thiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation","volume":"121","author":"Kaul","year":"2010","journal-title":"Circulation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/01.ATV.0000147897.57527.e4","article-title":"Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: A Go-DARTS study","volume":"24","author":"Doney","year":"2004","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/VHRM.S2397","article-title":"Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: A case-cohort study and meta-analyses","volume":"4","author":"Zafarmand","year":"2008","journal-title":"Vasc. Heal. Risk Manag."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.3892\/etm.2016.3858","article-title":"Effects of curcumin on the apoptosis of cardiomyocytes and the expression of NF-\u03baB, PPAR-\u03b3 and Bcl-2 in rats with myocardial infarction injury","volume":"12","author":"Lv","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1139\/cjpp-2016-0150","article-title":"Effect of vitamin D on isoprenaline-induced myocardial infarction in rats: Possible role of peroxisome proliferator-activated receptor-\u03b3","volume":"95","author":"Allam","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mahajan, U.B., Chandrayan, G., Patil, C.R., Arya, D.S., Suchal, K., Agrawal, Y.O., Ojha, S., and Goyal, S.N. (2017). The Protective Effect of Apigenin on Myocardial Injury in Diabetic Rats mediating Activation of the PPAR-\u03b3 Pathway. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040756"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1159\/000478641","article-title":"Qiliqiangxin Attenuates Adverse Cardiac Remodeling after Myocardial Infarction in Ovariectomized Mice via Activation of PPAR\u03b3","volume":"42","author":"Shen","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e12438","DOI":"10.1111\/jpi.12438","article-title":"Melatonin suppresses platelet activation and function against cardiac ischemia\/reperfusion injury via PPAR\u03b3\/FUNDC1\/mitophagy pathways","volume":"63","author":"Zhou","year":"2017","journal-title":"J. Pineal Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10735-018-9793-0","article-title":"Chrysin attenuates interstitial fibrosis and improves cardiac function in a rat model of acute myocardial infarction","volume":"49","author":"Yang","year":"2018","journal-title":"J. Mol. Histol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"173389","DOI":"10.1016\/j.ejphar.2020.173389","article-title":"Chrysin rescues rat myocardium from ischemia-reperfusion injury via PPAR-\u03b3\/Nrf2 activation","volume":"883","author":"Rani","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"108572","DOI":"10.1016\/j.abb.2020.108572","article-title":"The molecular mechanism involved in cardioprotection by the dietary flavonoid fisetin as an agonist of PPAR-\u03b3 in a murine model of myocardial infarction","volume":"694","author":"Garg","year":"2020","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_72","first-page":"1261","article-title":"Preventive effect of hesperidin modulates inflammatory responses and antioxidant status following acute myocardial infarction through the expression of PPAR\u2011\u03b3 and Bcl\u20112 in model mice","volume":"17","author":"Meng","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_73","first-page":"5477","article-title":"Theacrine attenuates myocardial fibrosis after myocardial infarction via the SIRT3\/\u03b2-catenin\/PPAR\u03b3 pathway in estrogen-deficient mice","volume":"23","author":"Song","year":"2019","journal-title":"Eur Rev Med Pharmacol. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2009.07.026","article-title":"Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction","volume":"619","author":"Goyal","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cbi.2010.03.030","article-title":"Modulation of PPAR-\u03b3 by telmisartan protects the heart against myocardial infarction in experimental diabetes","volume":"185","author":"Goyal","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yjmcc.2018.03.006","article-title":"Enhanced MiR-711 transcription by PPAR\u03b3 induces endoplasmic reticulum stress-mediated apoptosis targeting calnexin in rat cardiomyocytes after myocardial infarction","volume":"118","author":"Zhao","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1002\/jcb.26903","article-title":"miR-130 aggravates acute myocardial infarction-induced myocardial injury by targeting PPAR-\u03b3","volume":"119","author":"Chu","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: The AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3132\/dvdr.2007.042","article-title":"Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes","volume":"4","author":"Ratner","year":"2007","journal-title":"Diabetes Vasc. Dis. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/24\/9436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:43:49Z","timestamp":1760179429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/24\/9436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":79,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21249436"],"URL":"https:\/\/doi.org\/10.3390\/ijms21249436","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}